Skip to main content

Drug Interactions between cycloserine and Trecator

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

ethionamide cycloSERINE

Applies to: Trecator (ethionamide) and cycloserine

MONITOR: Coadministration with other neurotoxic antituberculosis agents such as isoniazid, ethionamide, and protionamide may potentiate the nervous system adverse effects of cycloserine or its prodrug, terizidone. Dizziness and drowsiness have been commonly reported when cycloserine is used with isoniazid. Less commonly, convulsions have been reported during use of cycloserine with ethionamide, and a pellagra-like encephalopathy related to disturbances in pyridoxine metabolism has been reported during concomitant use with protionamide. Other nervous system adverse effects of these drugs that may increase in frequency during coadministration include depression, anxiety, psychoses, memory impairment, confusion, and peripheral neuropathy.

MANAGEMENT: Close monitoring for nervous system toxicities is recommended during treatment with cycloserine or terizidone, particularly when used in higher dosages (e.g., cycloserine greater than 500 mg/day) or in combination with other neurotoxic antituberculosis agents. Dosage adjustments may be necessary. Pyridoxine (vitamin B6) should be given to help minimize the risk and/or severity of neurologic effects. Patients should also be advised to avoid the consumption of alcohol, as it may increase the risk of nervous system adverse effects.

References (5)
  1. Mattila MJ, Nieminen E, Tiitinen (1969) "Serum levels, urinary excretion, and side-effects of cycloserine in the presence of isoniazid and p-aminosalicylic acid." Scand J Respir Dis, 50, p. 291-300
  2. (2001) "Product Information. Seromycin (cycloserine)." Dura Pharmaceuticals
  3. (2001) "Product Information. Trecator-SC (ethionamide)." Wyeth-Ayerst Laboratories
  4. Cerner Multum, Inc. "UK Summary of Product Characteristics."
  5. (2006) "Product Information. Isoniazid (isoniazid)." Barr Laboratories Inc

Drug and food interactions

Major

cycloSERINE food

Applies to: cycloserine

GENERALLY AVOID: Coadministration with alcohol may potentiate some of the central nervous system adverse effects of cycloserine and its prodrug, terizidone. These effects may include dizziness, drowsiness, depression, anxiety, psychoses, memory impairment, confusion, and convulsions.

MANAGEMENT: Patients should be advised to avoid the consumption of alcohol during treatment with cycloserine or terizidone. The use of these medications is contraindicated in patients with chronic alcohol consumption or alcoholism.

MONITOR CLOSELY: Coadministration with caffeine may potentiate some of the central nervous system adverse effects of cycloserine and its prodrug, terizidone. These effects may include insomnia, excitability, irritability, anxiety, tremor, psychoses, and convulsions.

MANAGEMENT: Caution is advised when cycloserine or terizidone is used with caffeine. Consumption of certain beverages or stimulants with very high caffeine levels should be avoided as a precautionary measure.

References (2)
  1. (2001) "Product Information. Seromycin (cycloserine)." Dura Pharmaceuticals
  2. Cerner Multum, Inc. "UK Summary of Product Characteristics."
Major

ethionamide food

Applies to: Trecator (ethionamide)

GENERALLY AVOID: The concomitant use of protionamide with alcohol may enhance the central nervous system exciting effect of protionamide. The mechanism is not known. Excessive use of alcohol with another thiocarbamide derivative ethionamide, has been reported to precipitate a psychotic reaction. In addition, alcohol tolerance is reported to be reduced during protionamide treatment.

MANAGEMENT: Consumption of alcohol during protionamide treatment should be avoided. The manufacturer of ethionamide also advises that excess alcohol consumption should be avoided during ethionamide therapy (US).

References (2)
  1. (2001) "Product Information. Trecator-SC (ethionamide)." Wyeth-Ayerst Laboratories
  2. World Health Organization (2020) WHO Public Assessment Reports (WHOPARs) https://extranet.who.int/pqweb/medicines/prequalification-reports/whopars

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer